Plasma Glucose-lowering Action of Allantoin is Induced by Activation of Imidazoline I-2 Receptors in Streptozotocin-induced Diabetic Rats

Abstract

Allantoin, an active principle of yam, is documented to lower plasma glucose in diabetic rats. However, action mechanisms of allantoin remain obscure. It has been indicated that metformin shows ability to activate imidazoline I-2 receptors (I-2R) to lower blood sugar. Allantoin has also a chemical structure similar to metformin; both belong to guanidinium derivative. Thus, it is of special interest to know the effect of allantoin on I-2R. In the present study, the marked plasma glucose-lowering action of allantoin in streptozotocin-induced type-1 like diabetic rats was blocked by specific I-2R antagonist, BU224, in a dose-dependent manner. Also, the increase of β-endorphin release by allantoin was blocked by BU224 in the same manner. Otherwise, amiloride at the dose sufficient to block I-2AR abolished the allantoin-induced β-endorphin release and inhibited the blood glucose-lowering action of allantoin markedly but not completely. The direct effect of allantoin on glucose uptake in isolated skeletal muscle was also blocked by BU224. Also, the phosphorylation of AMPK in isolated skeletal muscle was raised by allantoin in a concentration-dependent manner. More­over, insulin sensitivity in diabetic rats was markedly increased by allantoin and this action was also blocked by BU224. These results suggest that allantoin has an ability to activate imidazoline I-2R while I-2AR is linked to the increase of β-endorphin release and I-2BR is related to other actions including the influence in skeletal muscle for lowering of blood glucose in type-1 like diabetic rats. Thus, allantoin can be developed to treat diabetic disorders in the future.

Key words

allantoin - amiloride - β-endorphin - diabetes - imidazoline receptor

• References

• 1 Sagara K, Ojima M, Suto K, Yoshida T. Quantitative determination of allantoin in Dioscorea rhizome and an Oriental pharmaceutical preparation, hachimi-gan, by high-performance liquid chromatography. Planta Medica 1989; 55: 93
• 2 Shestopalov AV, Shkurat TP, Mikashinovich ZI, Kryzhanovskaia IO, Bogacheva MA, Lomteva SV, Prokof’ev VP, Gus’kov EP. Biological functions of allantoin. Izv Akad Nauk Seriia Biologicheskaia/Rossiiskaia Akad Nauk 2006; 541-545
• 3 Sato K, Iemitsu M, Aizawa K, Ajisaka R. DHEA improves impaired activation of Akt and PKC zeta/lambda-GLUT4 pathway in skeletal muscle and improves hyperglycaemia in streptozotocin-induced diabetes rats. Acta Physiol (Oxf) 2009; 197: 217-225
• 4 Gao X, Li B, Jiang H, Liu F, Xu D, Liu Z. Dioscorea opposita reverses dexamethasone induced insulin resistance. Fitoterapia 2007; 78: 12-15
• 5 Hsu JH, Wu YC, Liu IM, Cheng JT. Dioscorea as the principal herb of Die-Huang-Wan, a widely used herbal mixture in China, for improvement of insulin resistance in fructose-rich chow-fed rats. J Ethnopharmacol 2007; 112: 577-584
• 6 Wang SJ, Liu HY, Gao WY, Chen HX, Yu JG, Xiao PG. Characterization of new starches separated from different Chinese yam (Dioscorea opposita Thunb.) cultivars. Food Chem 2006; 99: 30-37
• 7 Niu CS, Chen W, Wu HT, Cheng KC, Wen YJ, Lin KC, Cheng JT. Decrease of Plasma Glucose by Allantoin, an Active Principle of Yam (Dioscorea spp.), in Streptozotocin-Induced Diabetic Rats. J Agr Food Chem 2010; 58: 12031-12035
• 8 Dardonville C, Rozas I. Imidazoline binding sites and their ligands: An overview of the different chemical structures. Med Res Rev 2004; 24: 639-661
• 9 Ernsberger P, Graves ME, Graff LM, Zakieh N, Nguyen P, Collins LA, Westbrooks KL, Johnson GG. I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann New York Acad Sci 1995; 763: 22-42
• 10 Morgan NG, Chan SL, Mourtada M, Monks LK, Ramsden CA. Imidazolines and pancreatic hormone secretion. Ann New York Acad Sci 1999; 881: 217-228
• 11 Lui TN, Tsao CW, Huang SY, Chang CH, Cheng JT. Activation of imidazoline I2B receptors is linked with AMP kinase pathway to increase glucose uptake in cultured C2C12 cells. Neurosci Lett 2010; 474: 144-147
• 12 Chang CH, Wu HT, Cheng KC, Lin HJ, Cheng JT. Increase of beta-endorphin secretion by agmatine is induced by activation of imidazoline I(2A) receptors in adrenal gland of rats. Neurosci Lett 2010; 468: 297-299
• 13 Tesson F, Pripbuus C, Lemoine A, Pegorier JP, Parini A. Subcellular-Distribution of Imidazoline-Guanidinium-Receptive Sites in Human and Rabbit Liver – Major Localization to the Mitochondrial Outer-Membrane. J Biol Chem 1991; 266: 155-160
• 14 Cheng JT, Liu IM, Tzeng TF, Tsai CC, Lai TY. Plasma glucose-lowering effect of beta-endorphin in streptozotocin-induced diabetic rats. Horm Metab Res 2002; 34: 570-576
• 15 Lee JP, Chen W, Wu HT, Lin KC, Cheng JT. Metformin can activate imidazoline I-2 receptors to lower plasma glucose in type 1-like diabetic rats. Horm Metab Res 2011; 43: 26-30
• 16 Chang SL, Lin KJ, Lin RT, Hung PH, Lin JG, Cheng JT. Enhanced insulin sensitivity using electroacupuncture on bilateral Zusanli acupoints (ST 36) in rats. Life Sci 2006; 79: 967-971
• 17 Chang CH, Tsao CW, Huang SY, Cheng JT. Activation of imidazoline I(2B) receptors by guanidine to increase glucose uptake in skeletal muscle of rats. Neurosci Lett 2009; 467: 147-149
• 18 Hwang SL, Liu IM, Tzeng TF, Cheng JT. Activation of imidazoline receptors in adrenal gland to lower plasma glucose in streptozotocin-induced diabetic rats. Diabetologia 2005; 48: 767-775
• 19 Cheng JT, Hsu JH, Wu YC, Liou SS, Liu IM, Huang LW. Mediation of Endogenous beta-endorphin by Tetrandrine to Lower Plasma Glucose in Streptozotocin-induced Diabetic Rats. Evid-Based Compl Alt 2004; 1: 193-201
• 20 Liu IM, Liou SS, Cheng JT. Mediation of beta-endorphin by myricetin to lower plasma glucose in streptozotocin-induced diabetic rats. J Ethnopharmacol 2006; 104: 199-206
• 21 Evans AAL, Smith ME. Effect of beta-endorphin C-terminal peptides on glucose uptake in isolated skeletal muscles of the mouse. Peptides 1997; 18: 165-167
• 22 Ou HY, Cheng JT, Yu EH, Wu TJ. Metformin increases insulin sensitivity and plasma beta-endorphin in human subjects. Horm Metab Res 2006; 38: 106-111
• 23 Hsu CT, Liu IM, Cheng JT. Increase of beta-endorphin biosynthesis in the adrenal gland of streptozotocin-induced diabetic rats. Neurosci Lett 2002; 318: 57-60
• 24 Krug AW, Ehrhart-Bornstein M. Adrenocortical dysfunction in obesity and the metabolic syndrome. Horm Metab Res 2008; 40: 515-517
• 25 Lachaudpettiti V, Podevin RA, Chretien Y, Parini A. Imidazoline-Guanidinium and Alpha-2-Adrenergic Binding-Sites in Basolateral Membranes from Human Kidney. Eur J Pharm-Molec Ph 1991; 206: 23-31
• 26 Coupry I, Atlas D, Podevin RA, Uzielli I, Parini A. Imidazoline-Guanidinium Receptive Site in Renal Proximal Tubule – Asymmetric Distribution, Regulation by Cations and Interaction with an Endogenous Clonidine Displacing Substance. J Pharmacol Exp Ther 1990; 252: 293-299
• 27 Joshi MS, Ferguson B, Johnson FK, Johnson RA, Parthasarathy S, Lancaster JR. Receptor-mediated activation of nitric oxide synthesis by arginine in endothelial cells. Nitric Oxide-Biol Ch 2006; 14: A47-
• 28 Miralles A, Olmos G, Sastre M, Barturen F, Martin I, Garciasevilla JA. Discrimination and Pharmacological Characterization of I-2-Imidazoline Sites with [H-3] Idazoxan and Alpha-2 Adrenoceptors with [H-3] Rx821002 (2-Methoxy Idazoxan) in the Human and Rat Brains. J Pharmacol Exp Ther 1993; 264: 1187-1197
• 29 Diamant S, Eldargeva T, Atlas D. Imidazoline Binding-Sites in Human Placenta – Evidence for Heterogeneity and a Search for Physiological-Function. Brit J Pharmacol 1992; 106: 101-108
• 30 Li JX, Zhang Y. Imidazoline I2 receptors: target for new analgesics?. European journal of pharmacology 2011; 658: 49-56
• 31 Romer L, Wurster S, Savola JM, Raasmaja A. Identification and characterization of the imidazoline I2b-binding sites in the hamster brown adipose tissue as a study model for imidazoline receptors. Arch Physiol Biochem 2003; 111: 159-166
• 32 Miralles A, Esteban S, Sastre-Coll A, Moranta D, Asensio VJ, Garcia-Sevilla JA. High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain. Eur J Pharmacol 2005; 518: 234-242